Prostate & Urologic Cancers
Overview
Genitourinary cancers represent the broadest and most common group of all malignancies, including testicular cancer, bladder cancer, kidney cancer and prostate cancer.
Our Prostate & Urologic Cancer disease group is at the forefront of treating these cancers. We also have expertise treating mediastinal germ cell cancers, Paget’s disease of the scrotum, penile cancer, rhabdoid tumor of the kidney, stromal tumors of the testis, small cell/neuroendocrine cancer of the prostate or bladder, teratoma, transitional cell cancer, urethral cancer, urachal cancer, and urothelial cancer.
Through multidisciplinary care, education, and research, our physicians are helping improve the survival and quality of life of patients.
Our associated DCI Center for Prostate & Urologic Cancers, which brings together a multidisciplinary team of more than 20 clinicians and 30 laboratory-based researchers, is a national leader in the areas of health disparities, immunotherapy, population sciences and RNA targets and therapeutics.
Treatment
Prostate Cancer
Our physicians who treat prostate cancer are members of Duke’s nationally-ranked urology and cancer programs and lead the field in screening, diagnosing and treating prostate cancer. Duke Cancer Center is a top referral center for prostate cancer.
Utilizing the latest medical, surgical and radiation therapies, we specialize in difficult-to-treat prostate cancer.
We practice a first do no harm approach, optimizing treatment tailored to those men most likely to benefit while minimizing risks, and incorporating a multi-disciplinary team based approach to patient counseling, risk stratification, and therapy based on individual patient’s health conditions, prostate cancer subtypes and preferences. We are also strong advocates of active surveillance for small, nonaggressive prostate cancer.
We offer a variety of minimally invasive treatments such as:
• Surgery
• Radiation Therapy
• Energy Ablative Techniques
• Targeted Therapies
LEARN MORE ABOUT OUR PROSTATE CANCER TREATMENTS
Kidney Cancer
Our physicians specialize in aggressive and difficult-to-treat kidney cancers. Duke Cancer Center is a top referral center for kidney cancer.
The best approach for our patients depends on the size, stage and location of the cancer.
One or more of the following therapies may be recommended:
• Surgery
• Energy Ablative Techniques
• Radiation Therapy
• Targeted Therapies
*While not considered a standard treatment for kidney cancer, chemotherapy may also be used when kidney cancer doesn’t respond to immunotherapy or targeted therapy.
LEARN MORE ABOUT OUR KIDNEY CANCER TREATMENTS
Bladder Cancer
Our physicians specialize in aggressive and difficult-to-treat bladder cancer. Duke Cancer Center is a top referral center for bladder cancer.
Our specialists use the latest medical and surgical advances to treat bladder cancer at every stage, including non-invasive, invasive and metastatic disease. Sophisticated techniques target treatment of the bladder tumor (s) while minimizing disruption to healthy tissue. If needed, our skilled surgeons can perform complex surgery and reconstruction suited to individual patient circumstances and preferences.
The following are some of the treatment options available:
• Surgery for Cancer Removal
• Reconstruction Surgery
• Targeted Therapies
Our patients also have access to an enhanced recovery program — one of only a handful of programs in the United States —to keep our patients healthier and get back to the comfort of home sooner after major surgery.
The program is designed to reduce in-hospital time and lessen the chance for complications by promoting early feeding and physical activity while maximizing pain control using a multimodal approach that reduces the need for opioids.
LEARN MORE ABOUT OUR BLADDER CANCER TREATMENTS
Testicular Cancer
Research
Prostate Cancer
Our translational researchers study:
• Molecular Mechanisms and Biomarkers
• Immunotherapies
• Biology of Cancer Disparities
• Prostate Cancer Diagnostics
• Focal Therapy
LEARN MORE ABOUT OUR PROSTATE CANCER RESEARCH
Kidney Cancer
Our translational researchers study:
• Molecular Mechanisms and Biomarkers
• Development of Perioperative Treatment
• Development of Novel Treatments and Combinations for Aggressive Kidney Cancer
• Study of Non-Clear Cell Renal Cell Carcinomas
• Treatment-Related Toxicities
LEARN MORE ABOUT OUR KIDNEY CANCER RESEARCH
Bladder Cancer
Our translational researchers study:
• Tumor Immunology and Immunotherapy
• Hyperthermia and Heat-Targeted Therapy
• Diagnostic Test Development
• Drug Development and Clinical Trials
• Bladder Cancer Genetics
Clinical Trials
Our program is spearheading clinical trials that are leading to improvements in the treatment of prostate, bladder, kidney and testicular cancer.
Our prostate cancer clinical trials include health disparities biology, novel immunotherapies, precision/predictive medicine and biomarkers of aggressive disease, multi-disciplinary trials, and survivorship studies.
Our kidney cancer and bladder cancer clinical trials include the development, identification and testing of novel immunotherapies, the study of precision/predictive medicine and biomarkers of aggressive disease, and survivorship studies.
Prostate & Urologic Cancer Specialists
We discover, develop and deliver the future of cancer care . . . now.
Urologic Oncology
Samuel H. Eaton, MD
Michael N. Ferrandino, MD
Brant A. Inman, MD, MS
Thomas A. Longo, MD
Judd W. Moul, MD
Thomas J. Polascik, MD
Cary N. Robertson, MD
Medical Oncology
Andrew Armstrong, MD, MsC
William R. Berry, MD
Daniel J. George, MD
Michael R. Harrison, MD
Megan McNamara, MD
Tian Zhang, MD
Radiation Oncology
Carol A. Hahn, MD
Bridget F. Koontz, MD
W. Robert Lee, MD, MEd, MS
Scott L. Sailer, MD
Jordan Torok, MD
Make An Appointment
To make an appointment, please call 888.275.3853.
Additional Contacts
Brian Senter, MBA, Administrative Director
Phone: 919.613.1920
Julia Rasmussen, Assistant Research Practice Manager
Phone: 919.681.9822
Make A Gift
Donate to support breakthrough research in prostate and urologic cancers.